Medisse has completed the move to its new location in Ede. The building is situated at the grounds of Kernhem, near the centre of Ede. read more
Ede, 28 January 2013, Medisse B.V., announced the closure of a Series B equity financing round for the clinical trial of its lead product FlexiSurge® Adhesion Barrier. New investor IIG joins… read more
Medisse has completed its move to its new premises in Leusden, bringing the whole company to one location. The overall increase of space will be a key contributor to the company’s projected … read more
Medisse has completed its move to its new premises in Leusden, bringing the whole company to one location. The overall increase of space will be a key contributor to the company’s projected … read more
Medisse is pleased to announced that its shareholders have appointed Alexander Vos to its Supervisory Board. Mr. Vos is currently CEO of Pharmacell , a company that provides contract service… read more
Medisse has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge® biomaterial in accordance with the international ISO 10993 standards. Regulatory agenci… read more
Medisse is happy to announce that it received a grant "Overijssel innoveert verder" from the local authorities from the Dutch province Overijssel. read more
Medisse announced today the closure of an equity financing round by BioGeneration Ventures and Crédit Agricole Private Equity. read more
Poly(1,3-trimethylene carbonate) networks as anti adhesion barriers, S.V.N. de Vos, B.W. Hellebrekers, D.W. Grijpma, J. Feijen. read more
Article: S.V.N. de Vos, S.A. Koopmans, J.M.M. Hooymans, J. Feijen, D.W. Grijpma, Poly(1,3-trimethylene carbonate) networks as a resorbable scleral buckle, Journal of Controlled Release, 132 … read more